Analysts ponder soaring Arca shares

What's up at Arca Biopharma? Analysts have been scratching their heads trying to figure out why, after the developer announced a new patent on Friday--hardly earthshattering news--its stock would go up more than 200 percent. TheStreet's Adam Feuerstein suggests it could be the result of momentum trading, with a higher price building steam. Ironically, he adds, Arca disclosed that it still hasn't reached agreement with the FDA on its special protocol assessment for the new Phase III the agency demanded on bucindolol. And that's the kind of news that normally wouldn't excite investors. Report

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.